Prevalence of Renal Impairment and Associated Conditions Among HCV-Infected Persons in the Chronic Hepatitis Cohort Study (CHeCS)
Authors:
- Anne C. MoormanAMAnne C. Moorman
- Xin TongXTXin Tong
- Philip R. SpradlingPSPhilip R. Spradling
- Loralee B. RuppLRLoralee B. Rupp
- Stuart C. GordonSGStuart C. Gordon
- Mei LuMLMei Lu
- Eyasu H. TeshaleETEyasu H. Teshale
- Joseph A. BoscarinoJBJoseph A. Boscarino
- Connie M. TrinactyCTConnie M. Trinacty
- Mark A. SchmidtMSMark A. Schmidt
- Scott D. HolmbergSHScott D. Holmberg
- 23 May 2016
- journal article
- research article
- Published by Springer Nature in Digestive Diseases and Sciences
- Vol. 61 (7) , 2087-2093
Abstract
Background Guidelines for the treatment of HCV-infected persons were updated in August 2015 with new recommendations for patients with renal impairment. Treatment is imperative for patients with severe, renal-associated extrahepatic manifestations of HCV infection. Aims We sought to describe the prevalence of these conditions among current HCV-infected patients in a population-based prospective, observational cohort study at four large US health systems. Methods Data from cohort patients with chronic HCV infection during 2012 were analyzed for the period from 2006 to 2013. We determined the prevalence of mild to moderately impaired renal function defined as having the most recent estimated glomerular filtration rate [eGFR] ≤ 80 ml/min/1.73 m2, with severe impairment defined as eGFR < 30 ml/min/1.73 m2, based on the treatment guidelines. Prevalence of extrahepatic conditions was ascertained using ICD9-codes. Results Among 5772 persons, the prevalence of eGFR ≤ 80 was 33 % and eGFR < 30 was 2 %, including among patients with hepatic fibrosis. Diagnosed extrahepatic renal manifestations were rare: vasculitis- 0.2 %, nephrotic syndrome- 0.3 %, and cryoglobulinemia- 0.9 %. Conclusions While the prevalence of severe renal impairment and diagnosed extrahepatic manifestations was low, mild-to-moderate renal impairment was common in HCV patients, including those with advanced liver fibrosis for whom the need for treatment is urgent.Keywords
Funding Information
- CDC Foundation
This publication has 24 references indexed in Scilit:
- The validity of serum markers for fibrosis staging in chronic hepatitis B and CJournal of Viral Hepatitis, 2014
- Hepatitis C virus associated glomerulopathiesWorld Journal of Gastroenterology, 2014
- Noninvasive Serum Fibrosis Markers for Screening and Staging Chronic Hepatitis C Virus Patients in a Large US CohortClinical Infectious Diseases, 2013
- Higher prevalence of chronic kidney disease and shorter renal survival in patients with chronic hepatitis C virus infectionHepatology International, 2011
- Impact of hepatitis C virus infection and other comorbidities on survival in patients on dialysisJournal of Viral Hepatitis, 2007
- Hepatitis C virus: from entry to renal injury--facts and potentialsNephrology Dialysis Transplantation, 2007
- Relationship between Hepatitis C and Chronic Kidney DiseaseJournal of the American Society of Nephrology, 2006
- Special Article: National Surveillance of Dialysis‐Associated Diseases in the United States, 2002Seminars in Dialysis, 2005
- Relationship between hepatitis C and microalbuminuria: Results from the NHANES IIIKidney International, 2005
- Risk of death and liver cirrhosis in anti‐HCV‐positive long‐term haemodialysis patientsNephrology Dialysis Transplantation, 2001